When was GBT founded?

GBT was founded in 2011 and raised its 1st funding round 1 year after it was founded.

Where is GBT located?

GBT is headquartered in San Francisco, United States. It is registered at San Francisco (United States).

How many employees does GBT have?

As of Sep 30, 2026, the latest employee count at GBT is 71.

Is GBT a funded company?

GBT is a funded company, having raised a total of $88.7M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jun 14, 2012.

How much is GBT worth?

The last known valuation of GBT was $***** as of Apr 20, 2020.

When was the latest funding round of GBT?

GBT's latest funding was a $***** Series B round on Jan 05, 2015, with participation from 4 investors. Its primary sector is Rare Diseases. In United States, the Rare Diseases sector has seen $1.24B in funding in 2026 to date.

Where does GBT rank among its competitors?

GBT ranks 11th amongst 32 active competitors, of which 5 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Editas Medicine, which secured $2M in Dec, 2023.

Who are the top competitors of GBT?

GBT's top competitors include Kedrion, Fulcrum Therapeutics and Sierra Oncology. Among them, Editas Medicine secured the most recent funding round in December, 2023.

GBT - 2026 Company Profile, Funding & Competitors

Q: Is GBT an acquired company?

GBT got acquired by Pfizer on Aug 08, 2022.

GBT is an acquired company based in San Francisco (United States), founded in 2011. It operates as a Developer of small molecules for the treatment of sickle cell disease. GBT has raised $88.7M in funding from investors like RA Capital Management, Deerfield and Wellington, with last known valuation of $*****. The company has 32 active competitors, including 5 funded and 12 that have exited. Its top competitors include companies like Kedrion, Fulcrum Therapeutics and Sierra Oncology.

Company Details

Developer of small molecules for the treatment of sickle cell disease. The company lead candidate, voxelotor (GBT440) is in Phase 3 trials and being investigated for the treatment of sickle cell disease. The candidate is a hemoglobin S polymerization inhibitor and its mechanism of action is modulation of hemoglobin affinity for oxygen.

Website: gbt.com
Social
Email ID: *****@gbt.com
Phone Number: +1 **********
Registered Address: San Francisco (United States)

Key Metrics

Founded Year

2011

Location

San Francisco, United States

Stage

Acquired

Total Funding

$88.7M in 2 rounds

Latest Funding Round

Series B, Jan 05, 2015, $*****

Last Known Valuation

$***** as on Apr 20, 2020

Investors

RA Capital Management & 9 more

Ranked

11^th among 32 active competitors

Employee Count

71 as on Sep 30, 2026

Similar Companies

Kedrion & 44 more

Exit Details

Acquired by Pfizer (Aug 08, 2022)

View GBT's full profile

GBT is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Global Blood Therapeutics, Inc. CIN: 274825712 , Belgium, Active	Dec 31, 2010	-	457 (As on Dec 31, 2021)	-

GBT got acquired by Pfizer on Aug 08, 2022 at an acquisition amount of $*****.

Click here to take a look at GBT's acquisition in detail

GBT has raised a total funding of $88.7M over 2 rounds. Its first funding round was on Jun 14, 2012. Its latest funding round was a Series B round on Jan 05, 2015 for $*****. 4 investors participated in its latest round. GBT has 10 institutional investors.

Here is the list of recent funding rounds of GBT:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 05, 2015	3246580	Series B	7126858	6035188	9294635	1831918
Jun 14, 2012	7011330	Series A	1488031	4095129	3803279	Third Rock Ventures

Access funding benchmarks and valuations. Sign up today!

View details of GBT's funding rounds and investors

GBT's employee count trend

GBT has 71 employees as of Sep 26. Here is GBT's employee count trend over the years:

Uncover GBT's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of GBT include Kedrion, Fulcrum Therapeutics and Sierra Oncology. Here is the list of Top 10 competitors of GBT, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Kedrion 2001, Barga (Italy), Acquired	Developer of plasma-derived products for hemophilia and immune system deficiencies	$189M	CDP Equity, Ampersand Capital & 4 others	63/100
2nd	Fulcrum Therapeutics 2015, Cambridge (United States), Public	Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases	$115M	Foresite Capital, Google Ventures & 15 others	61/100
3rd	Sierra Oncology 2003, Vancouver (Canada), Acquired	Developer of targeted therapies to treat cancer	$75M	Vivo Capital, Adams Street Partners & 18 others	59/100
4th	Editas Medicine 2013, Cambridge (United States), Public	Developer of genomic medicines using gene editing technology for diseases	$210M	T. Rowe Price, Foresite Capital & 21 others	59/100
5th	Emmaus Medical 2000, Torrance (United States), Acquired	Developer of small molecule therapeutics for the treatment of sickle cell anemia and sickle ß0-thalassemia	-	E&Investment, Mitsubishi UFJ Capital & 4 others	57/100
6th	Cyclerion 2018, Cambridge (United States), Public	Developer of therapies for treating sickle cell disease and diabetic nephropathy	-	Lincoln Park Capital, Invus & 6 others	55/100
7th	Modus Therapeutics 2011, Stockholm (Sweden), Series B	Developers of polysaccharide based drug for the treatment of Sickle Cell Disease	$22.9M	Healthcap, The Foundation for Baltic and East European Studies ... & 4 others	55/100
8th	Octapharma 1983, Lachen (Switzerland), Unfunded	Developer of plasma derived therapeutics for multiple diseases	-	-	53/100
9th	LogicBio 2013, Lexington (United States), Acquired	Developer of viral vectors for the treatment of genetic and infectious diseases	$49M	Arix Bioscience, Pontifax & 6 others	52/100
10th	AOP Health 1996, Vienna (Austria), Unfunded	Developer of treatments for rare diseases	-	-	50/100
11th	GBT 2011, San Francisco (United States), Acquired	Developer of small molecules for the treatment of sickle cell disease	$88.7M	Perceptive Advisors, Avoro Capital & 8 others	49/100